Cargando…

Evaluation of New Biphasic Calcium Phosphate Bone Substitute: Rabbit Femur Defect Model and Preliminary Clinical Results

Autogenous bone grafting, used to repair bone defects, is limited and the donor site can experience complications. Compared to autogenous bone graft, artificial bones have different porosity, which might make them suitable alternatives to bone grafts. Here, two porous biphasic calcium phosphate bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yeong-Jang, Pao, Jwo-luen, Chen, Chiang Sang, Chen, Yu-Chun, Chang, Chun-Chien, Hung, Fang-Ming, Chang, Chih-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325870/
https://www.ncbi.nlm.nih.gov/pubmed/28286465
http://dx.doi.org/10.1007/s40846-016-0203-3
_version_ 1782510440311422976
author Chen, Yeong-Jang
Pao, Jwo-luen
Chen, Chiang Sang
Chen, Yu-Chun
Chang, Chun-Chien
Hung, Fang-Ming
Chang, Chih-Hung
author_facet Chen, Yeong-Jang
Pao, Jwo-luen
Chen, Chiang Sang
Chen, Yu-Chun
Chang, Chun-Chien
Hung, Fang-Ming
Chang, Chih-Hung
author_sort Chen, Yeong-Jang
collection PubMed
description Autogenous bone grafting, used to repair bone defects, is limited and the donor site can experience complications. Compared to autogenous bone graft, artificial bones have different porosity, which might make them suitable alternatives to bone grafts. Here, two porous biphasic calcium phosphate bone substitutes, namely Bicera™ and Triosite™, are used in an animal study and clinical practice to find a suitable porosity for implantation. Bicera™ and Triosite™ consist of 60 wt% hydroxyapatite and 40 wt% β-tricalcium phosphate, with the porosity of Bicera™ (82%) being higher than that of Triosite™ (70%). In the animal study, the implantation procedure was carried out on twenty-four female New Zealand rabbits. 12 weeks after implantation, the new bones were well infiltrated into the Bicera™ and Triosite™ bone grafts. In the clinical study, patients with comminuted fracture, fracture nonunion, or arthrodesis were included in the study of bone substitution with Bicera™. 27 patients underwent fracture fixation treatment. Bone healing of 22.22% (6/27) of patients happened within 3 months after the surgery, and that of 66.67% (18/27) of patients happened within 6 months. These results reveal that Bicera™ has good incorporation with host bone, and that new bone is able to grow within the porous structure, giving it high potential in the treatment of bone defects.
format Online
Article
Text
id pubmed-5325870
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-53258702017-03-09 Evaluation of New Biphasic Calcium Phosphate Bone Substitute: Rabbit Femur Defect Model and Preliminary Clinical Results Chen, Yeong-Jang Pao, Jwo-luen Chen, Chiang Sang Chen, Yu-Chun Chang, Chun-Chien Hung, Fang-Ming Chang, Chih-Hung J Med Biol Eng Original Article Autogenous bone grafting, used to repair bone defects, is limited and the donor site can experience complications. Compared to autogenous bone graft, artificial bones have different porosity, which might make them suitable alternatives to bone grafts. Here, two porous biphasic calcium phosphate bone substitutes, namely Bicera™ and Triosite™, are used in an animal study and clinical practice to find a suitable porosity for implantation. Bicera™ and Triosite™ consist of 60 wt% hydroxyapatite and 40 wt% β-tricalcium phosphate, with the porosity of Bicera™ (82%) being higher than that of Triosite™ (70%). In the animal study, the implantation procedure was carried out on twenty-four female New Zealand rabbits. 12 weeks after implantation, the new bones were well infiltrated into the Bicera™ and Triosite™ bone grafts. In the clinical study, patients with comminuted fracture, fracture nonunion, or arthrodesis were included in the study of bone substitution with Bicera™. 27 patients underwent fracture fixation treatment. Bone healing of 22.22% (6/27) of patients happened within 3 months after the surgery, and that of 66.67% (18/27) of patients happened within 6 months. These results reveal that Bicera™ has good incorporation with host bone, and that new bone is able to grow within the porous structure, giving it high potential in the treatment of bone defects. Springer Berlin Heidelberg 2017-01-19 2017 /pmc/articles/PMC5325870/ /pubmed/28286465 http://dx.doi.org/10.1007/s40846-016-0203-3 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Chen, Yeong-Jang
Pao, Jwo-luen
Chen, Chiang Sang
Chen, Yu-Chun
Chang, Chun-Chien
Hung, Fang-Ming
Chang, Chih-Hung
Evaluation of New Biphasic Calcium Phosphate Bone Substitute: Rabbit Femur Defect Model and Preliminary Clinical Results
title Evaluation of New Biphasic Calcium Phosphate Bone Substitute: Rabbit Femur Defect Model and Preliminary Clinical Results
title_full Evaluation of New Biphasic Calcium Phosphate Bone Substitute: Rabbit Femur Defect Model and Preliminary Clinical Results
title_fullStr Evaluation of New Biphasic Calcium Phosphate Bone Substitute: Rabbit Femur Defect Model and Preliminary Clinical Results
title_full_unstemmed Evaluation of New Biphasic Calcium Phosphate Bone Substitute: Rabbit Femur Defect Model and Preliminary Clinical Results
title_short Evaluation of New Biphasic Calcium Phosphate Bone Substitute: Rabbit Femur Defect Model and Preliminary Clinical Results
title_sort evaluation of new biphasic calcium phosphate bone substitute: rabbit femur defect model and preliminary clinical results
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325870/
https://www.ncbi.nlm.nih.gov/pubmed/28286465
http://dx.doi.org/10.1007/s40846-016-0203-3
work_keys_str_mv AT chenyeongjang evaluationofnewbiphasiccalciumphosphatebonesubstituterabbitfemurdefectmodelandpreliminaryclinicalresults
AT paojwoluen evaluationofnewbiphasiccalciumphosphatebonesubstituterabbitfemurdefectmodelandpreliminaryclinicalresults
AT chenchiangsang evaluationofnewbiphasiccalciumphosphatebonesubstituterabbitfemurdefectmodelandpreliminaryclinicalresults
AT chenyuchun evaluationofnewbiphasiccalciumphosphatebonesubstituterabbitfemurdefectmodelandpreliminaryclinicalresults
AT changchunchien evaluationofnewbiphasiccalciumphosphatebonesubstituterabbitfemurdefectmodelandpreliminaryclinicalresults
AT hungfangming evaluationofnewbiphasiccalciumphosphatebonesubstituterabbitfemurdefectmodelandpreliminaryclinicalresults
AT changchihhung evaluationofnewbiphasiccalciumphosphatebonesubstituterabbitfemurdefectmodelandpreliminaryclinicalresults